Abstract
Large scale outbreaks of the SARS-CoV-2 Delta variant have occurred in numerous settings, including universities. An outbreak of the SARS-CoV-2 Delta AY.25 lineage associated with a university campus with multiple transmission events was identified; genomic analyses characterized this outbreak and complemented contract tracing and wastewater surveillance strategies that strengthened overall public health response actions.
Epidemiologic and clinical data routinely gathered through contact tracing and public health investigations were matched to genomic sequencing of SARS-CoV-2 positive samples belonging to a suspect cluster identified through ongoing phylogenomic analyses. Continued phylogenetic analyses were conducted to describe the AY.25 outbreak. Wastewater collected twice weekly from sites across campus was tested for SARS-CoV-2 by RT-qPCR, and subsequently sequenced to identify variants.
The AY.25 outbreak was defined by a single mutation (C18804T) and comprised 379 genomes from SARS-CoV-2 positive cases associated with the university and community. Several undergraduate student gatherings and congregate living settings on campus likely contributed to the rapid spread of COVID-19 across the university with secondary transmission into the community. The clade defining mutation was also found in wastewater samples collected from around student dormitories during “move-in”, a week before the semester began, and 9 days before cases were identified.
Genomic, epidemiologic, and wastewater surveillance provided evidence that an AY.25 clone was likely imported into the university setting just prior to the onset of the Fall 2021 semester, rapidly spread through a subset of the student population, and then subsequent spillover occurred in the surrounding community. The university and local public health department worked closely together to facilitate timely reporting of cases, identification of close contacts, and other necessary response and mitigation strategies. The emergence of new SARS-CoV-2 variants and potential threat of other infectious disease outbreaks on university campuses presents an opportunity for future comprehensive One Health genomic data driven, targeted interventions.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The study did not receive any specific funding; the genomic sequencing efforts was supported by the Arizona Department of Health Services and the NARBHA Institute.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
This work was conducted in collaboration with a local public health agency as a public health surveillance activity, involving genomic sequencing and analysis of de-identified remnant biospecimens, and therefore is exempt from needing human subjects research board approval. This work used ONLY openly available de-identified viral genomic data from SARS-CoV-2 positive individuals, available through the public database GISAID (www.gisaid.org). GISAID Accession IDs used in this work are available in a supplemental table or will be made available upon request by the authors.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All genomic data presented in this work were obtained from a publicly available dataset hosted by GISAID. The data used in the present work are contained in the manuscript or available upon reasonable request to the authors.
